technical: Mechanism of action of lenalidomide

[Guest guest]

Mechanism of action of lenalidomide (Revlimid) in hematological malignancies

Copying:

Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds

derived by modifying the chemical structure of thalidomide to improve its

potency and reduce its side effects.

Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the

neurologic side effects of sedation and neuropathy and has emerged as a drug

with activity against various hematological and solid malignancies. It is

approved by FDA for clinical use in myelodysplastic syndromes with deletion

of chromosome 5q and multiple myeloma.

Lenalidomide has been shown to be an immunomodulator, affecting both

cellular and humoral limbs of the immune system.

It has also been shown to have anti-angiogenic properties.

Newer studies demonstrate its effects on signal transduction that can partly

explain its selective efficacy in subsets of MDS. Even though the exact

molecular targets of lenalidomide are not well known, its activity across a

spectrum of neoplastic conditions highlights the possibility of multiple

target sites of action. "

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171/

Patients Against Lymphoma

www.Lymphomation.org

Evidence-based information on lymphoma, independent of health industry

funding